How Long Does Filler Take to Settle? The Borderline Cases, and How to Call Them

Facial filler usually finishes settling in about two weeks, and the outer edge in the manufacturers' own files is 30 days, which is the length of the symptom diary patients kept in the FDA-cleared trials for Juvéderm and Restylane products. Two weeks is an average across the face rather than a rule for your face: Juvéderm's labeling reports swelling in 30 of 100 temple patients and 93 of 100 lip patients. Nothing in any settling timeline covers pain, pale or mottled skin, or a change in vision. Those are same-hour calls, on day one or day five.

Your injected area sets the settling range, and the spread is enormous

The single number you were given at checkout averages areas that behave nothing alike. Here is what the FDA-cleared patient labeling reports, area by area, from diaries patients filled in themselves.

| Area | Product studied | Reported swelling | How long swelling lasted | Result lasted | |---|---|---|---|---| | Temples | Juvéderm Voluma XC | 30 of 100 | Gone within 3 days for 21 of every 100 treated | Up to 13 months in 73% | | Cheeks | Juvéderm Voluma XC | 86 of 100 | Side effects generally 2 to 4 weeks | Up to 2 years in a majority | | Nasolabial folds | Juvéderm Vollure XC | 86 of 100 | 55% of those affected cleared in 1–3 days; 19% ran 8–14 days | Through 18 months in 59.4% | | Lips and perioral | Juvéderm Volbella XC | 93 of 100 | Usually 2 weeks or less | 1 year in over 60% | | Under-eyes | Restylane Eyelight | 85 of 100 | 77% of those affected cleared in 2–7 days; 2% ran 14–28 days | Up to 18 months |

The files do not even measure duration the same way, which tells you how loosely "settling" is defined by the industry selling it. Jawline and marionette lines sit outside the table deliberately: Juvéderm Volux XC took its FDA approval for jawline definition on July 29, 2022 and was studied through 12 months, while marionette lines are usually treated with products approved for the folds beside them, so any settling figure quoted there is borrowed.

Volume and depth move the number too. Trial medians ran from 0.6 mL per nasolabial fold with Vollure XC to 2.6 mL for lips with Volbella XC, and Voluma XC's cheek labeling states the consequence plainly: adverse events were seen more frequently in subjects who received a large volume and in subjects who were older.

On the hour of peak swelling I have to report a gap rather than a figure. The regulatory files contain no peak-hour measurement. Their only hour-numbers are the 24-hour restriction on exercise and heat, and Restylane Eyelight's median return to social comfort: four hours after a needle, twelve after a cannula. The 24-to-72-hour peak taught in clinics comes from practice guidance rather than trial data, though it matches the 24-hour line the 2018 expert consensus in Aesthetic Plastic Surgery drew for immediate-onset complications.

Normal swelling improves. A vascular complication gets worse.

Normal post-injection swelling is proportionate to what was done, soft, and headed downward after the first day or two. A normal bruise is round, sits where the needle went, and cycles through red, purple, and yellow-green. Both hurt the way a knock hurts: tender when pressed, quiet when left alone.

A vascular occlusion, where product has entered or compressed a vessel, reads differently. The ACE Group guideline published in the Journal of Clinical and Aesthetic Dermatology in 2020 describes severe pain usually felt at the time of injection, though delayed presentations are documented; blanching that persists after the needle is out and may spread into a net-like reticulated pattern; dusky discoloration more typical several hours later; and coolness that is not apparent immediately. Press the area and release. Skin with blood flow re-pinks in about two seconds; skin that stays pale, refills slowly, or mottles in a branching pattern beyond the injection site is not bruising.

Timing is a discriminator, not a reassurance. Juvéderm's postmarket surveillance summary states that blood vessel blockage generally occurred from immediately to one week after injection. Day four is inside that window.

Around 2022 I stopped leading escalation copy with "swelling lasting more than a few days." It had been my top line for years because it is what patients actually call about. Unusual pain replaced it, for a reason I can defend: pain is the earliest sign in the ACE description, arriving in the chair, while swelling duration cannot be judged until several days have already passed. A first line that cannot fire until Thursday is not a first line.

The four symptoms that are a call, not a settling question

Juvéderm's patient labeling lists them under "When should I call my doctor?" and instructs patients to call immediately for:

1. Changes in your vision.
2. Signs of a stroke, including sudden difficulty speaking, numbness or weakness in the face, arms or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion.
3. White appearance of the skin.
4. Unusual pain during or shortly after treatment.

The FDA's patient page widens the third item to a white, grey, or blue appearance of skin near the injection, and names where blockages are reported most often: the glabella, in and around the nose, the forehead, and around the eyes. A second tier warrants a same-day call rather than an emergency one: significant pain away from the injection site, redness or swelling lasting more than a few days, and any side effect appearing weeks or months later.

Speed is the point. The ACE Group's high-dose pulsed hyaluronidase protocol, given hourly until tissue reperfuses, has prevented necrosis in virtually all cases since its adoption, even when started up to 48 hours after treatment. The eye is less forgiving. Beleznay and colleagues, reviewing the world literature in Aesthetic Surgery Journal in 2019, found 48 published cases of vision loss after filler between January 2015 and September 2018; 20.8 percent recovered sight completely, 16.7 percent partially.

The strongest argument against all of this is a good one. A call list this sensitive floods after-hours lines, costs clinics money, and trains patients to distrust ordinary healing. Base rates back the objection: Alam and colleagues surveyed 370 board-certified dermatologists in JAMA Dermatology in 2021, covering 1.7 million syringes, and found one occlusion per 6,410 syringes with needles and one per 40,882 with cannulas. Risk never exceeded one per 5,000 for any product-and-device combination. Most worried calls are nothing, and I grant it. What it cannot price is the asymmetry: a wasted call costs a few minutes of a nurse's evening, a missed one is scored in hours of ischaemia against tissue that does not grow back. And 106 of those 370 dermatologists, 28.6 percent, had seen at least one occlusion. Rare per syringe, common per career.

I should be straight about what I am not. I have never injected anyone and never will, so I cannot tell you how a cannula feels crossing the sub-orbital plane or whether your left cheek needed another 0.2 mL. What I can vouch for is the receiving end of the phone, and what your labeling actually instructs.

What to record in the first days

Photographs and timestamps do the work memory cannot. Five steps, starting the day of treatment.

1. Photograph in fixed conditions. Front and both 45-degree angles, same light and distance, once daily for seven days. Different lighting invents and erases swelling.
2. Log the clock time, not just the date. Occlusion is assessed in hours. "Tuesday" is not usable clinical information; "Tuesday 6:40 p.m." is.
3. Rate pain 0 to 10 daily and record the direction. A 4 falling to a 2 is healing. A 2 climbing to a 5 is the pattern that gets you seen.
4. Check capillary refill daily. Press the treated area five seconds, release, count. Doing it on day one, while everything is fine, is what makes day four's result mean anything.
5. Keep the product record. Brand and formulation, lot number, millilitres per side, needle or cannula, injector's name, and the after-hours number. Write that number somewhere you can find it while frightened.

I learned the last point by getting it wrong. Early on I produced an aftercare sheet where the call-now instruction sat in the sixth paragraph, beneath a tidy explanation of what hyaluronic acid is. Two of the three people I asked to read it back could not tell me what number to call. The sheet had already gone out. Since then the call line goes first, above the chemistry and the reassurance.

Massage, heat, and the wait-it-out reflex

The labeling is narrower than the internet here. Juvéderm's patient information says to minimize strenuous exercise and exposure to extensive sun or heat within the first 24 hours, because each can increase temporary redness, swelling, and itching. Restylane Eyelight extends the temperature caution until initial swelling and redness resolve. Ice is permitted; heat is not.

Self-massage is where advice goes wrong most often. Massage and warm compresses appear in occlusion protocols alongside repeated hyaluronidase, and that pairing causes most of the harm I see: a patient reads that massage and heat treat an occlusion, applies both at home, and skips the call that would have brought the enzyme. They are steps in a supervised protocol; alone they are a delay.

The wait-it-out reflex has the same structure. That 30-day diary was a data-collection window, not a permission slip to ignore a month. Volbella XC's labeling records seven patients whose lumps or swelling appeared weeks to months after treatment, and both Juvéderm files describe delayed inflammation at old filler sites following illness, vaccination, or dental work. The 2018 consensus classifies anything past four weeks as delayed onset. A lump arriving in November from filler placed in June is a new event, not late settling.

Use the review your injector planned, not a number you read

These products define a touch-up as an additional injection given roughly two weeks to one month after the first, and the trials leaned on it heavily. Eighty-two percent of Voluma XC cheek patients took one at a month, 65 percent of temple patients, 62 percent of Volbella XC lip patients. Restylane Eyelight scheduled visits at 1, 3, 6, 9, and 12 months with an optional touch-up at one month.

Read that as a design decision. The manufacturers did not judge their own results at day fourteen; they judged at one and three months, with a correction built into the plan. Assessing your face on day five means assessing edema. A booked two- or four-week review is your clearance, and it is where the labeling wants delayed problems raised.

Deciding whether more filler still makes sense

Keep a running record across years rather than per appointment: dates, products, lot numbers, volume per side, injector, and one photograph at a fixed angle each time. Two things get decided from it. First, whether you are replacing volume or accumulating it, which matters because Voluma XC's labeling ties higher adverse event rates to larger volumes and older patients. Second, whether the duration you paid for is materialising. If a product labeled to last two years in the cheeks is topped up at eight months, the conversation shifts from settling to suitability.

Whether the aesthetic result is worth continuing is not my call, and I would distrust anyone in my job who claimed otherwise. The filler history belongs in your medical record alongside allergies and medications, because a dentist, a vaccine, or a bad flu can wake up product injected years earlier, and whoever examines your swollen face will not know what is in it unless you can say.

Frequently asked questions

Do fillers look better after they settle?

Usually, yes. Day-one volume includes swelling, so what you see leaving the clinic is not the result you keep. In Juvéderm Voluma XC's cheek trial, 82 percent of patients still chose a touch-up one month later, meaning the settled result was more often under-corrected than over-corrected once edema left. Judge at one month.

What should be avoided after facial filler?

FDA-cleared Juvéderm labeling says to minimize strenuous exercise and exposure to extensive sun or heat for the first 24 hours, since all three can increase redness, swelling, and itching. Restylane Eyelight extends the temperature caution until initial swelling and redness resolve. Avoid self-massage and home heat unless your injector specifically instructs it.

How long does lip filler take to settle?

Lips swell more than almost anywhere else on the face. In Juvéderm Volbella XC's FDA labeling, 93 of 100 patients reported swelling and 89 reported bruising, and those reactions usually lasted two weeks or less. Sixty-two percent went on to a touch-up at one month, which is the reasonable point to judge lips.

How long does cheek filler take to settle?

Cheeks run longer than the two-week rule of thumb suggests. Juvéderm Voluma XC's labeling reports swelling in 86 of 100 patients, with side effects generally lasting two to four weeks. Eighty-two percent of trial patients took a touch-up one month later, so assess cheeks at four weeks rather than two.

How long does under-eye filler take to settle?

In the FDA trial for Restylane Eyelight, approved for undereye hollows in June 2023, 85 percent of patients reported swelling and 77 percent of those cleared within two to seven days. Bruising ran longer: about a third of bruised patients still had it past a week.

When should I call my injector instead of waiting it out?

Call immediately for vision changes, stroke signs, white or grey skin near the injection, or unusual pain during or shortly after treatment. Those four items come from the product labeling itself. Call the same day for significant pain away from the site, or redness and swelling lasting more than a few days.